Mednet Logo
Community

Would you recommend adjuvant immunotherapy after platinum-based chemotherapy for patients with in resected NSCLC with HER2 mutations?

Would PD-L1 expression level or HER2 mutation subtype influence your decision?
1 Answer
Mednet Member
Mednet MemberInvited Expert
Medical Oncology · Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Answered on

The benefit of immunotherapy in HER2 mutant NSCLC is an active topic of debate. I do not typically recommend adjuvant immunotherapy after platinum-based chemotherapy for patients with resected HER2-mutant NSCLC. Tumors with oncogenic drivers, specifically EGFR, ALK, ROS, RET, and HER2, show reduced ...

Join for free or sign in to see the full answer